Department of Endocrinology, Metabolism and Nephrology, Kochi Medical School, Kochi University, Kohasu, Oko-cho, Nankoku, Kochi783-8505, Japan.
Department of Pediatrics, Kochi Medical School, Kochi University, Kohasu, Oko-cho, Nankoku, Kochi783-8505, Japan.
Rom J Intern Med. 2022 Mar 17;60(1):85-89. doi: 10.2478/rjim-2021-0032. Print 2022 Mar 1.
We herein report the first case of lupus-related protein-losing enteropathy associated with pseudo-pseudo Meigs' syndrome. Lupus-related protein-losing enteropathy and pseudo-pseudo Meigs' syndrome are extremely rare complications in patients with systemic lupus erythematosus, Both have a similar clinical course characterized by producing marked ascites, and respond to steroids in typical cases. However, in our case, steroid monotherapy was inadequate and the addition of hydroxychloroquine was effective for their treatment. Furthermore, no reports have previously confirmed elevated CA 125 levels with lupus-related protein-losing enteropathy or increased 99mTc-HSA activity with pseudo-pseudo Meigs' syndrome. In addition, we are the first to report an evaluation of the histopathology of lupus-related protein-losing enteropathy. Previously reported cases have been described as being caused by either pseudo-Meigs's syndrome or lupus-related protein-losing enteropathy as the cause of the rare pathology that causes marked pleural effusion and ascites in patients with systemic lupus erythematosus, but it has not been evaluated whether the other is co-occurring. Our case highlights that there is a potential case of overlapping lupus-related protein-losing enteropathy and pseudo-Pseudo-Meigs's syndrome. Furthermore, it is possible that patients with marked ascites with elevated CA 125 levels were mistakenly diagnosed with Meigs's syndrome or pseudo-Meigs's syndrome associated with malignant or benign ovarian tumors and underwent surgery. Clinicians should not forget SLE with pseudo-Pseudo-Meigs's syndrome as one of the differential diagnoses for marked ascites with elevated CA 125 levels.
我们在此报告首例狼疮相关蛋白丢失性肠病伴假性假性梅格斯综合征的病例。狼疮相关蛋白丢失性肠病和假性假性梅格斯综合征是系统性红斑狼疮患者极为罕见的并发症,两者均具有相似的临床病程,表现为大量腹水,典型病例对类固醇治疗有反应。然而,在我们的病例中,单独使用类固醇治疗效果不佳,加用羟氯喹对其治疗有效。此外,以前没有报道过狼疮相关蛋白丢失性肠病会导致 CA125 水平升高,或假性假性梅格斯综合征会导致 99mTc-HSA 活性升高。此外,我们是第一个评估狼疮相关蛋白丢失性肠病的组织病理学的。以前报告的病例被描述为假性梅格斯综合征或狼疮相关蛋白丢失性肠病导致系统性红斑狼疮患者罕见的胸腔积液和腹水病理,但是否同时存在其他情况尚未进行评估。我们的病例提示可能存在重叠的狼疮相关蛋白丢失性肠病和假性假性梅格斯综合征。此外,可能有 CA125 水平升高的大量腹水患者被误诊为梅格斯综合征或假性梅格斯综合征伴恶性或良性卵巢肿瘤,并接受了手术。临床医生不应忘记假性假性梅格斯综合征伴发的系统性红斑狼疮作为 CA125 水平升高的大量腹水的鉴别诊断之一。